GKOS vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GKOS and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | GKOS | REGN |
|---|---|---|
| Company Name | Glaukos Corporation | Regeneron Pharmaceuticals, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 5.40 billion USD | 62.64 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 25, 2015 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of GKOS and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GKOS | REGN |
|---|---|---|
| 5-Day Price Return | 5.17% | 4.42% |
| 13-Week Price Return | -0.71% | -0.93% |
| 26-Week Price Return | -38.45% | -12.35% |
| 52-Week Price Return | -27.58% | -50.62% |
| Month-to-Date Return | 9.36% | 8.35% |
| Year-to-Date Return | -37.21% | -17.03% |
| 10-Day Avg. Volume | 0.76M | 0.98M |
| 3-Month Avg. Volume | 1.00M | 1.20M |
| 3-Month Volatility | 35.07% | 46.56% |
| Beta | 0.77 | 0.31 |
Profitability
Return on Equity (TTM)
GKOS
-12.52%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
GKOS has a negative Return on Equity of -12.52%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
REGN
15.11%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GKOS
-21.43%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
GKOS has a negative Net Profit Margin of -21.43%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
REGN
31.37%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
GKOS
-22.33%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
GKOS has a negative Operating Profit Margin of -22.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
REGN
27.02%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | GKOS | REGN |
|---|---|---|
| Return on Equity (TTM) | -12.52% | 15.11% |
| Return on Assets (TTM) | -9.63% | 11.81% |
| Net Profit Margin (TTM) | -21.43% | 31.37% |
| Operating Profit Margin (TTM) | -22.33% | 27.02% |
| Gross Profit Margin (TTM) | 76.34% | 86.46% |
Financial Strength
Current Ratio (MRQ)
GKOS
5.51
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
GKOS’s Current Ratio of 5.51 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
REGN
4.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GKOS
0.09
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, GKOS’s Debt-to-Equity Ratio of 0.09 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
REGN
0.09
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GKOS
-28.92
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
GKOS has a negative Interest Coverage Ratio of -28.92. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
REGN
243.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | GKOS | REGN |
|---|---|---|
| Current Ratio (MRQ) | 5.51 | 4.60 |
| Quick Ratio (MRQ) | 4.52 | 3.78 |
| Debt-to-Equity Ratio (MRQ) | 0.09 | 0.09 |
| Interest Coverage Ratio (TTM) | -28.92 | 243.95 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GKOS
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
GKOS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
GKOS
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
GKOS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | GKOS | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
GKOS
--
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
P/E Ratio data for GKOS is currently unavailable.
REGN
13.68
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.68 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
GKOS
11.93
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
With a P/S Ratio of 11.93, GKOS trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
REGN
4.29
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.29 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
GKOS
7.71
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
GKOS’s P/B Ratio of 7.71 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
REGN
1.89
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | GKOS | REGN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 13.68 |
| Price-to-Sales Ratio (TTM) | 11.93 | 4.29 |
| Price-to-Book Ratio (MRQ) | 7.71 | 1.89 |
| Price-to-Free Cash Flow Ratio (TTM) | 467.73 | 17.16 |